Established in 2000, Taro UK has the benefit of Taro’s global resources. With 52 years of experience in developing, manufacturing, and marketing medications used in countries around the world, Taro looks forward to providing the UK with an expanding line of affordable, high-quality branded and generic pharmaceuticals.
This website contains valuable information about Taro UK products for dispensing doctors, pharmacists and consumers. Please visit often to learn more about the ways in which Taro can serve you.
February 03, 2016
Taro to Announce Third Quarter Results on February 10, 2016
December 28, 2015
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
November 24, 2015
Amendment to Previously Filed 6-K (Proxy Statement)
November 03, 2015
Taro Provides Results for September 30, 2015
October 27, 2015
Taro to Announce Second Quarter Results on November 3, 2015
September 21, 2015
Taro’s Keveyis™ (dichlorphenamide) 50 mg Tablets Now Available for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis
August 10, 2015
FDA Approves Taro’s Keveyis™ (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and Hypokalemic Periodic Paralysis